Niagen Bioscience Inc. has published the transcript of its Third Quarter 2025 Earnings Conference Call, which took place on Tuesday, November 4, 2025. The event was attended by key company executives, including Chief Executive Officer Rob Fried, Chief Financial Officer Ozan Pamir, and Senior Vice President of Scientific and Regulatory Affairs Dr. Andrew Shao, who joined for the Q&A session. During the call, management discussed the company's financial results for the third quarter of 2025, research and development updates, clinical trial plans and timing, and future regulatory filings. The expansion of Niagen products into new markets, business development opportunities, and investor interest were also highlighted. Management noted the company's ongoing commitment to innovation and market growth. "We remain focused on advancing our clinical programs and expanding our product reach," stated the CEO. The CFO commented on financial performance, emphasizing the company's approach to future cash needs and operating performance. The call included forward-looking statements regarding anticipated results of operations and business prospects. The full transcript can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.
Comments